Publication:
BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters

Simple item page
dc.contributor.authorUĞURLU, MUSTAFA ÜMİT
dc.contributor.authorsKombak, Faruk Erdem; Ozkan, Naziye; Ugurlu, Mustafa Umit; Kaya, Handan
dc.date.accessioned2022-03-14T09:09:17Z
dc.date.available2022-03-14T09:09:17Z
dc.date.issued2019
dc.description.abstractObjective: To investigate the association of the BRAFV600E mutation with papillary thyroid carcinoma using clinical, morphological and prognostic parameters. We also intend to assess the utility of the BRAFV600E immunohistochemistry and compare it with BRAF polymerase chain reaction (RT-PCR). Material and Method: We applied BRAFV600E immunohistochemistry in a cohort of 107 papillary carcinomas, 19 adenomas and 13 normal thyroid tissues that was chosen retrospectively between 2011 and 2015. Statistical analysis was based on semiquantitative immunohistochemistry findings. We also applied BRAF RT-PCR in a subgroup of 14 papillary carcinomas, 13 metastatic lymph nodes and 4 adenomas that was chosen randomly. Results: In regard to the comparison of BRAFV600E immunohistochemistry and BRAF RT-PCR, a 3+ nuclear and cytoplasmic immunoexpression was considered 'positive The BRAFV600E mutation was most frequently observed in classic variant cases. No mutation was detected in follicular variant cases. The mutational status of the primary tumour and the lymph node metastasis was consistent. A significant relationship of the BRAFV600E mutation was found with prognostic factors such as higher pT stage, classic variant, lymphatic invasion, perineural invasion, lower mitotic index, lack of tumour capsule, intrathyroidal spread and extrathyroidal extension. Conclusion: Immunohistochemistry, using the VE1 clone, is a reliable technique for detection of the BRAFV600E mutation. Our results with immunohistochemistry are consistent with a previous effort. In our study, despite the correlation between some pathological prognostic parameters and the BRAFV600E mutation; poor prognosis was found to be irrelevant overall. Morphological parameters seem to be keener than the BRAFV600E mutation. Nevertheless, different series display different results, possibly due to environmental factors. Considering this and the proven success of targeted therapies against the BRAFV600E mutation a thorough assessment would be important.
dc.identifier.doi10.5146/tjpath.2018.01448
dc.identifier.eissn1309-5730
dc.identifier.issn1018-5615
dc.identifier.pubmed30632125
dc.identifier.urihttps://hdl.handle.net/11424/242646
dc.identifier.wosWOS:000466572300001
dc.language.isoeng
dc.publisherFEDERATION TURKISH PATHOLOGY SOC
dc.relation.ispartofTURKISH JOURNAL OF PATHOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectThyroid
dc.subjectPapillary carcinoma
dc.subjectBRAFV600E
dc.subjectImmunohistochemistry
dc.subjectReverse Transcriptase PCR
dc.subjectPrognosis
dc.subjectBRAF V600E MUTATION
dc.subjectLYMPH-NODE METASTASIS
dc.subjectBRAF(V600E) MUTATION
dc.subjectRISK
dc.subjectRECURRENCE
dc.subjectPREDICTOR
dc.subjectTRENDS
dc.subjectIMPACT
dc.subjectTUMORS
dc.titleBRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters
dc.typearticle
dspace.entity.typePublication
local.avesis.id9ed76255-51ad-4fbb-87d9-9b74438ac9a9
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.indexed.atTRDIZIN
local.journal.numberofpages9
oaire.citation.endPage91
oaire.citation.issue2
oaire.citation.startPage83
oaire.citation.titleTURKISH JOURNAL OF PATHOLOGY
oaire.citation.volume35
relation.isAuthorOfPublication76044dc9-a441-4103-b46d-5d995fec91d4
relation.isAuthorOfPublication.latestForDiscovery76044dc9-a441-4103-b46d-5d995fec91d4

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kombak et al. - 2019 - Brafv600e immunohistochemistry in papillary thyroi.pdf
Size:
4.92 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs